Philip founded Geneva Network in 2015. His main research interests are the intersection of intellectual property, trade, and health policy. Formerly he was an official at the World Intellectual Property Organization (WIPO) in Geneva, where he worked in its Global Challenges Division on a range of IP and health issues. Prior to his time with WIPO, Philip worked as director of policy for International Policy Network, a UK-based think tank, as well as holding research positions with the Adam Smith Institute and Reform, both in London. He has also worked as a political risk consultant and a management consultant. He is a regular columnist in a wide range of international newspapers and has published a number of academic studies. He holds degrees from the London School of Economics and Durham University (UK). He is also a Senior Fellow at the Institute for Democracy and Economic Affairs, Malaysia.
Pharmaceutical tariffs could be a barrier to access to medicines. This Working Paper looks at current levels of vaccine and pharmaceutical tariffs worldwide, and examines trade flows amongst the biggest exporting and importing nations.
What’s happened in the first six months of Geneva Network – new studies on IP,…
Free Trade Agreements (FTAs) containing TRIPS-Plus intellectual property provisions have been widely criticised on the grounds they have the potential to raise medicine prices and undermine access to medicines, particularly in developing countries.
In the Trans-Pacific Partnership (TPP) negotiations, the U.S. and Japan have proposed that TPP partners increase their period of regulatory data protection (RDP) for biologic medicines to align with practice in other countries.
Brand competition, underpinned by intellectual property rights, is the key to ending the global fake medicines crisis.
Geneva Network co-hosted its first event on 21 May, in Singapore, with our friends at…